同濟大學醫學菁英分論壇誠邀天下英才！

同濟大學

醫學菁英分論壇

誠邀天下英才

申報海外優青

只等你來！

論壇簡介

同濟大學醫學菁英論壇是在“同濟大學第十一屆國際青年學者論壇”框架下舉辦的重要活動，由同濟大學醫學院主辦，多家附屬醫院參與支持。論壇聚焦但不限于以下領域：腦與脊髓、心血管疾病、癌癥基礎與轉化、免疫學、干細胞、公共衛生、護理學、藥學、生物醫學工程、智能醫學工程、康復醫學工程等議題，凝聚海內外生命醫學領域的青年才俊，共同探討國際科技前沿話題，開拓學術視野，促進交流合作。

學院簡介

1907年，德國醫生埃里希·寶隆在上海創辦“德文醫學堂”，是同濟大學的前身，也是同濟醫學專業的開端。20世紀50年代，在全國高等學校院系布局調整中，醫學院整體遷出至武漢，但同濟人醫學情結至深，歷經百年滄桑后，同濟大學在新世紀之初重建醫學。2000年4月，同濟大學與原上海鐵道大學合并，在原上海鐵道大學醫學院的基礎上恢復設立了“同濟大學醫學院”。

經過快速發展，醫學學科的整體水平已躋身全國醫學院校前10%。2022年進入教育部直屬優質醫學院校名單（共18所院校入選）。在國際國內排名方面，QS（Quacquarelli Symonds）排名12，泰晤士高等教育THE排名11。2022年臨床醫學學科進入 ESI 世界前 1‰，8個醫學相關學科進入ESI世界前1% （世界前沿學科）。臨床醫學專業和康復物理治療專業被列入國家一流本科專業建設點。

平臺簡介

“十四五”期間，新增國家級、省部級科研平臺7個，包括心臟病全國重點實驗室，實現國家重點實驗室零的突破。新增了一批高層次科技創新領軍人才，柔性引進中國科學院院士1人，新增國際院士3人（劉中民教授當選俄羅斯工程院外籍院士，鄭加麟教授當選歐洲科學與藝術院院士（醫學學部）和歐洲科學院院士，孫毅教授當選俄羅斯工程院外籍院士），新增長江學者2人、杰青6人、優青11人。獲批各類科研項目1524項，科研項目立項總經費達12.585億元。截至2025年6月底，牽頭承擔國家重點研發計劃首席項目18項。獲批國家自然科學基金項目958項，獲資助直接經費4.75億元，其中重點重大類項目48項，包括基礎中心項目1項、創新群體2項。作為第一完成單位獲國家、省部級科學技術獎8項，包括國家科技進步獎二等獎1項、省部級科技一等獎6項、何梁何利獎1項。發表頂刊論文Nature 4篇、Cell 4篇、The Lancet 1篇、NEJM 3篇、BMJ 2篇等20分以上高影響力論文242篇。

2020年，學校在復興同濟醫科的道路上做出重大布局，將同濟大學滬西校區400余畝土地劃歸醫學發展使用，促進醫學院及附屬醫院在產學研、醫教研融合創新發展。2021年，學校投入近3億，改造修繕科研實驗室、實驗動物中心及生活體育設施空間2萬余平方米。2023年醫學院整體搬遷至滬西同濟醫學園區，未來滬西將建設成為在國際上具有較高影響力的醫學教育培訓的高地，醫學科學創新的高地，醫工交叉創新高地，區域融合產學研轉化高地。同時，與市區兩級政府深入合作，打造“一核、一城、一岸”，即以同濟大學醫學院為輻射源，打造生命健康策源核，成為國內一流的環同濟國家生物醫藥產業園區，并同步帶動建設TOP智創城、蘇河生命水岸，初步形成超百億級環同濟醫學園區經濟圈。

同濟大學附屬醫院

附屬第十人民醫院、附屬同濟醫院、附屬東方醫院、附屬上海市肺科醫院、附屬第一婦嬰保健院、附屬楊浦醫院、附屬養志康復醫院、附屬皮膚病醫院、附屬上海市第四人民醫院、附屬精神衛生中心、附屬普陀人民醫院

同濟大學醫學院網址

https://med.tongji.edu.cn/index.htm

2026年國家自然科學基金委“優秀青年科學基金項目（海外）”即將正式啟動，我們熱切期盼海內外青年學者參與本論壇，并依托同濟大學醫學院進行2026年海外優青項目申報！

1

項目定位

優秀青年科學基金項目（海外）旨在吸引和鼓勵在自然科學、工程技術等方面已取得較好成績的海外優秀青年學者（含非華裔外籍人才）回國（來華）工作，自主選擇研究方向開展創新性研究，促進青年科學技術人才的快速成長，培養一批有望進入世界科技前沿的優秀學術骨干，為科技強國建設貢獻力量。

2

待遇保障

?聘任崗位

評聘長聘教職、博士生導師。

?薪酬待遇

提供具有競爭力的薪酬；另享受教學津貼、科研績效及高水平成果獎勵。優秀對口的醫科研究人才，可獲得附屬醫院的附加薪酬。

?個人補貼

享受國家、上海市、大學及附屬醫院提供的相應生活補助共計400萬元以上。

?科研經費

200-600萬（國撥經費100-300萬，學校按照國撥經費1:1配套）；優秀對口的醫科研究人才，可支持獲得附屬醫院的附加科研啟動費，一事一議；科研經費最高可達800萬元。

?辦公設備

學院提供必需的辦公、實驗用房，在團隊建設、重大科研項目申請等方面給予傾斜支持。

?住房保障

提供周轉人才公寓，同時協助申請上海市其他人才公寓住房。

?入學醫療

辦理上海市戶口享受人才通道，依托市級人才政策及附屬學校協調解決子女入學入托，提供附屬醫院貼心醫療服務保障。

?招生

優先支持博士生和碩士生招生額度。

?團隊

提供5名學校資助博士后招收指標。

?申報輔導

提供貼心一站式服務，校院多級精細化有組織申報輔導，申報全程專業政策咨詢。

3

報名條件

1.遵守中華人民共和國法律法規，具有良好的科學道德，自覺踐行新時代科學家精神；

2.出生日期在1986年1月1日（含）以后；

3.具有博士學位；

4.研究方向主要為自然科學、工程技術等；

5.在2026年4月15日前，一般應在海外高校、科研機構、企業研發機構獲得正式教學或者科研職位，且具有連續36個月以上工作經歷；在海外取得博士學位且業績特別突出的，可適當放寬工作年限要求；

6.取得同行專家認可的科研或技術等成果，且具有成為該領域學術帶頭人或杰出人才的發展潛力；

7.申請人尚未全職回國（來華）工作，或者2025年1月1日以后回國（來華）工作。獲資助通知后須辭去海外工作或在海外無工作，全職回國（來華）工作不少于3年。

4

論壇舉辦

舉辦時間：

2025年12月26日-2025年12月28日

舉辦方式：

線上線下同步舉行，歡迎線下參觀交流。

5

報名方式

方式1

掃描二維碼登錄報名入口

https://www.wjx.top/vm/wFWTtuX.aspx#

（可復制鏈接至瀏覽器）

報名截止時間

2025年12月20日 12:00

方式2

通過郵件直接聯系各中心聯絡人進行報名。

心臟病臨床研究中心

The Clinical Research Center for Cardiovascular Diseases of Tongji University

滑動查看中英文介紹

Swipe to view Chinese and English introduction

同濟大學醫學院心臟病臨床研究中心（以下簡稱“心臟中心”）聚焦心臟病的源頭機制和瓶頸技術等重大科學問題，力爭取得心臟病理論研究的系列突破，研發出心臟病干預的創新藥物、創新技術、創新材料和創新器械，解決心臟病防治領域的難題。心臟中心堅持基礎研究與應用研究并重，研究與開發一體化，理論突破與技術發明全鏈條貫通。

心臟中心由中國科學院院士陳義漢教授領銜，研究團隊為國家基金委“卓越研究群體”、“創新研究群體”和教育部“創新團隊”。擁有心臟病全國重點實驗室、國家學科創新引智基地、國家臨床重點專科（心血管病）、國家衛健委冠心病、心律失常和結構性心臟病介入培訓基地和上海市心律失常研究中心等重要基地平臺。心臟中心的發展愿景是打造全球心臟病學“理論策源地”和“技術創新中心”。

The Clinical Research Center for Cardiovascular Diseases of Tongji University (hereinafter referred to as the "Heart Center"), focuses on major scientific questions such as the origins and underlying mechanisms of heart diseases, as well as key bottleneck technologies. It strives to achieve a series of breakthroughs in the theoretical research on heart diseases and to develop innovative drugs, technologies, materials, and devices for cardiac intervention, thereby addressing critical challenges in the prevention and treatment of heart diseases. The Heart Center adheres to the principle of giving equal emphasis to basic and applied research, promotes the integration of research and development, and ensures full-chain connectivity from theoretical breakthroughs to technological inventions.

The Heart Center is led by Professor Yi-Han Chen, an academician of the Chinese Academy of Sciences. The research team has been recognized as an "Outstanding Research Group" and "Innovative Research Group" by the National Natural Science Foundation of China, as well as an "Innovation Team" by the Ministry of Education. The Heart Center hosts several key platforms, including the State Key Laboratory of Cardiovascular Diseases, National Discipline Innovation and Talent Introduction Base, the National Clinical Key Specialty, the National Health Commission Training Bases for Interventional Therapies in Coronary Heart Disease, Arrhythmia, and Structural Heart Disease, and the Shanghai Arrhythmia Research Center. The development vision of the Heart Center is to build a global “source of theoretical innovation” and a “center of technological innovation” in cardiology.

聯絡人：金老師

郵箱：jxueling@yeah.net

腦與脊髓臨床研究中心

Clinical Center for Brain and Spinal Cord Research

滑動查看中英文介紹

Swipe to view Chinese and English introduction

同濟大學腦與脊髓臨床研究中心成立于2017年12月，是同濟大學六大臨床研究中心之一，依托同濟大學醫學院及附屬醫院管理及建設。現任主任為同濟大學醫學院院長、歐洲科學院院士鄭加麟教授。

為對接國家腦計劃，提升同濟大學腦與類腦科學研究水平，發揮一流學科引領作用，中心建立了以重大腦疾病為導向的腦科學交叉平臺，腦科學“基礎-臨床-人工智能交叉”研究體系，卓越腦科學及交叉學科人才培養體系等。中心利用學科傳統優勢，統籌課程體系，改革人才培養模式，加強醫工交叉，重視基礎與臨床轉化，培養卓越醫學與腦科學復合拔尖創新人才。積極參與國際腦計劃戰略合作，成立中瑞合作實驗室，邀請國內外神經領域專家定期學術交流，打造一流的學術高地，以一流管理服務為一流學科建設賦能。

中心研究方向涵蓋腦科學基礎科研及臨床轉化、腦科學與人工智能交叉、脊髓損傷及修復、臨床神經病學及疾病早期診斷，麻醉與腦功能等。中心科研機構包括教育部腦衰老相關疾病醫藥基礎研究創新中心、同濟大學脊柱脊髓損傷再生修復教育部重點實驗室、上海市麻醉與腦功能調控重點實驗室、同濟大學“腦智同飛”聯合研究中心、同濟大學醫學院人體解剖與組織胚胎學系、腦與類腦功能轉化研究所及中德腦科學中心等。

中心建立了同濟大學腦與脊髓臨床研究中心冠名研究員崗位制度；成立至今，已匯聚包括中國科學院院士、歐洲科學院院士、歐洲科學與藝術院院士、德國國家科學院院士、諾貝爾生理學或醫學獎獲得者、國家杰青、長江、國家重點引進人才工程專家及“四青”人才等骨干在內的多學科交叉腦科學基礎與臨床科研團隊。近五年來，同濟大學腦科學團隊已在Nature、Cell等國際著名學術期刊發表論文近30篇；獲得科技部重點研發計劃10余項，國家重大專項、國家自然科學基金重點專項、國際合作重大項目近10項，在研國家自然科學基金項目近70余項；圍繞腦科學領域多次獲得省部級獎勵。

研究方向涵蓋大腦感知原理和感知障礙致病機制，控制運動行為的環路機制和運動障礙的發病機理，腦機接口理論與技術，腦衰老與神經退行性疾病相關醫藥創新等。

Clinical Center for Brain and Spinal Cord Research of Tongji University was established in December 2017 and is one of the six major clinical research centers of Tongji University. It is managed by Tongji University School of Medicine. The current director is Professor Zheng Jialin, Dean of Tongji University School of Medicine, academic member of the European Academy of Sciences.

To elevate the research level of neuroscience and brain research of Tongji University, the center has established a cross-disciplinary research platform for major brain diseases, a research innovation system covering basic research, clinical research, and artificial intelligence, and the training system for excellent brain science and interdisciplinary talents. The center takes the advantages of traditional disciplines, constructs high level curriculum system, reforms the training program, strengthens the intersection of medicine and engineering, highlights the transformative medicine, and cultivates innovative talents expertizing in medicine and neuroscience. The center joined and is contributing to the International Brain Initiative, established the Sino-Swiss Laboratory, invites experts in the field of neurology for academic communications, creates a first-class academic atmosphere and services to facilitate the first-class research.

The research direction of the center contains basic neuroscience research and clinical translation, the intersection of neuroscience and artificial intelligence, spinal cord injury and repair, clinical neurology and early diagnosis of diseases, anesthesia and brain function, etc. The center includes multiple institutions, such as, the Medical Basic Research Innovation Center for Brain Aging and Related Diseases of the Ministry of Education, the Key Laboratory of Spinal Cord Injury Regeneration and Repair of Tongji University, the Shanghai Key Laboratory of Anesthesia and Brain Function Regulation, the Tongji University-iFlytek Joint Research Center, the Department of Human Anatomy and Embryology of Tongji University School of Medicine, Translational Research Institute of Brain and Brain-Like Intelligence, and the Sino-German Brain Research Center.

The center has gathered experts from basic and clinical research in neuroscience. In the past five years, the neuroscience team at Tongji University has published about 30 articles in high impact journals such as Nature and Cell. The center has been granted with National Program on Key Basic Research Projects, National Natural Science Foundation of China (General Program; Key Program; Major Program), and National Science Funds for Distinguished Young Scholars. The center received multiple National awards in the field of neuroscience.

聯絡人：齊老師

郵箱：shashaqi@tongji.edu.cn

癌癥中心

Cancer Center

滑動查看中英文介紹

Swipe to view Chinese and English introduction

同濟大學癌癥中心于2017年5月正式揭牌成立，該中心是同濟大學“十三五”建設“雙一流”大學醫學口三個重點建設項目之一，依托同濟大學醫學院和第十人民醫院、肺科醫院等我校各附屬醫院，整合現有的腫瘤臨床、基礎、轉化研究團隊，充分發揮同濟醫工結合優勢，力爭建設成為國內集臨床與科研為一體、以臨床為核心的具有特色和影響力的國內一流、世界知名的癌癥中心。

癌癥中心致力于腫瘤微環境基礎與轉化研究，包括腫瘤發生發展機制和轉化，腫瘤代謝和免疫微環境機制研究及靶向，腫瘤治療新靶點篩選及生物免疫治療臨床轉化等。近年來，中心所屬基礎和臨床團隊在JAMA、Cell、Nature、Cancer Cell、Cell Research、Nature Communications、Developmental Cell等國際知名期刊上發表重要學術論文360余篇，10分以上論文100余篇；申請或授權專利60余項，科研轉化成果1600萬余；承擔國家重點研發計劃、科技部重大研究計劃、國自然基金、上海市自然科學基金等課題百余項；并獲得教育部科學技術進步一等獎、中華醫學科技三等獎、上海市科學技術獎科技進步獎一等獎、高校科學研究成果自然科學獎一等獎多個科技獎項。

癌癥中心重視人才隊伍建設，由國家杰青、長江學者、科技部領軍人才、“萬人計劃”獲得者等優秀學科帶頭人領銜，先后引進和培養出國家杰青、優青、青年長江、上海市千人、啟明星人才、新優青、揚帆計劃獲得者和超級博士后等，培養的研究生也多次獲得國家獎學金、優秀畢業生等榮譽；同時積極探索國際合作，與美國紀念斯隆凱特琳癌癥中心、安德森癌癥中心、法國里昂高師、日本、德國等多所重點高校合作，拿到國家自然科學基金國際交流合作項目、上海市國際交流合作項目等。

The Cancer Center of Tongji University was officially inaugurated in May2017. This center is one of the key construction projects for the establishment of a "Double First-Class" medical university during the13th Five-Year Plan of Tongji University. It relies on the Tongji University School of Medicine and affiliated hospitals such as the Tenth People’s Hospital and the Pulmonary Hospital to integrate existing teams for clinical, basic, and translational cancer research. The center aims to leverage Tongji’s strengths in the integration of medicine and engineering, striving to become a leading cancer center in China that integrates clinical practice and research, with a focus on clinical care and a distinctive and influential presence recognized worldwide.

The Cancer Center is dedicated to foundational and translational research on the tumor microenvironment, including the mechanisms and translation of tumor development, tumor metabolism, and the immune microenvironment mechanisms as well as targeted therapies. It also focuses on screening new therapeutic targets for tumors and clinical translation of biological immunotherapies. In recent years, the center's basic and clinical teams have published over360 significant academic papers in prestigious international journals such as JAMA, Cell, Nature, Cancer Cell, Cell Research, Nature Communications, and Developmental Cell, including more than100 papers with an Impact Factor above10. Additionally, they have applied for or been granted over60 patents and achieved more than16 million in research translation results. The center has undertaken more than100 projects, including those from the National Key R&D Program, the Ministry of Science and Technology’s major research projects, the National Natural Science Foundation, and the Shanghai Natural Science Fund. It has also received multiple science and technology awards, including the First Prize of Scientific and Technological Progress from the Ministry of Education, the Third Prize of Chinese Medical Science and Technology, the First Prize of the Shanghai Science and Technology Progress Award, and the First Prize of the Natural Science Award for University Research Achievements.

The Cancer Center places great emphasis on talent development, led by outstanding academic leaders such as National Outstanding Young Scholars, Yangtze River Scholars, leading talents from the Ministry of Science and Technology, and recipients of the "Ten Thousand Talents Program." It has successively introduced and trained National Outstanding Young Scholars, Excellent Young Scientists, Young Yangtze River Scholars, Shanghai Thousand Talent Plan experts, Rising Stars, New Excellent Young Scholars, winners of the Sailing Plan, and Super Postdoctoral Fellows. Graduate students trained at the center have also received numerous honors, including National Scholarships and titles of Outstanding Graduates. Simultaneously, the center actively explores international collaborations with notable institutions such as the Memorial Sloan Kettering Cancer Center and the MD Anderson Cancer Center in the United States, as well as with key universities in France, Japan, and Germany. This has resulted in successful applications for international exchange and cooperation projects from the National Natural Science Foundation and the Shanghai International Exchange and Cooperation Project.

聯絡人：張老師

郵箱：zhy_yu2022@163.com

干細胞研究中心

Stem Cell Research Center

滑動查看中英文介紹

Swipe to view Chinese and English introduction

干細胞研究中心成立于2009年，經過十余年的發展，現已發展成為一支擁有4名國家級人才團隊和14名PI團隊、160余人組成的集基礎研究、轉化研究和臨床研究為一體的全鏈條研究基地。中心聚焦干細胞與胚胎發育、干細胞與模式動物、干細胞與組織器官再生三大研究方向，并取得系列國際領先研究成果：1）利用微量組學方法揭示了胚胎發育和干細胞靜息與激活機制；2）建立了在體細胞重編程方法并揭示了細胞命運轉換關鍵調控機制；3）利用基因編輯手段建立了非人靈長類大動物疾病模型；4）在細胞和器官同種異體移植通用型方面建立了具有我國自主知識產權的技術手段；5）在國際上率先開展了有關慢性堵塞性肺病等疾病的細胞移植臨床研究和移植產品研發。

干細胞研究中心圍繞上述方向，持續打造高水平人才梯隊，希望在神經、肺、皮膚與毛囊、骨關節、肝臟等干細胞與再生方向引進中外青年人才，在現有科技部中美干細胞研究中心和教育部重點實驗室的基礎上，形成學科高峰。

The Stem Cell Research Center was established in 2009 and has developed over a decade into a comprehensive center with the study of basic, translational, and clinical research of stem cells. It consists of a team of 4 national high-level talents and 14 principal investigators, with a total of over 160 members. The center focuses on three major research directions: stem cells and embryonic development, stem cells and model animals, stem cells and tissue and organ regeneration as well. It has achieved a series of internationally leading research results: 1) Revealed the mechanisms of embryonic development and stem cell quiescence and activation through micro-omics methods; 2) Established in vivo cell reprogramming methods and revealed key regulatory mechanisms of cell fate conversion; 3) Created non-human primate large animal disease models using gene editing techniques; 4) Established the technology with independent intellectual property rights in China for universal allogeneic cell and organ transplantation; 5) Pioneered clinical research and product development for cell transplantation in diseases such as chronic obstructive pulmonary disease.

The Stem Cell Research Center is committed to continuously building a high-level talent echelon around these directions, aiming to attract young talents from both home and abroad in the fields of stem cells and regeneration related to the nervous system, lungs, skin and hair follicles, bone and joints, liver, etc. Based on the existing Ministry of Science and Technology approved China US Research Center for Stem Cell and the Ministry of Education Key Laboratory, we seek to form a peak of academic disciplines.

聯系人：霍老師

郵箱：huorui2008@tongji.edu.cn

感染與免疫研究中心

Research Center for Infection and Immunity

滑動查看中英文介紹

Swipe to view Chinese and English introduction

同濟大學感染與免疫研究中心是同濟大學六大臨床研究中心之一，由病原體與宿主相互作用教育部重點實驗室、同濟大學傳染病與疫苗研究所和免疫學與病原生物學系組成。聚焦三個主要研究方向：①病原體感染與宿主相互作用的機制研究；②病原體感染促進其他疾病發生發展的臨床研究；③病原體感染新型診斷技術、免疫治療策略和藥物研發。

研究中心依托同濟大學醫學院并整合附屬第十人民醫院、附屬肺科醫院、附屬東方醫院和附屬皮膚病醫院優勢臨床學科群。擁有先進的檢測分析設備和儀器平臺。研究團隊由多位杰出學者組成，包括教育部長江學者、國家基金委杰青、國家萬人和國家基金委優青，承擔國家級項目40項，其中國家重大、重點項目14項；并取得了一系列重要原創成果，在國際刊物發表論文129篇，包括Nature、Nature Immunology、Cell Host & Microbe、Nature Microbiology等影響因子10以上刊物論文17篇。獲得教育部自然科學獎2項。

The Research Center for Infection and Immunity is one of the six major clinical research centers of Tongji University. It consists of the Key Laboratory of Pathogen-Host Interaction of the Ministry of Education, the Institute for Infectious Diseases and Vaccine Development of Tongji University, and the Department of Immunology and Pathogen Biology. It focuses on three main research directions: ① the mechanism of pathogen infection and host interaction; ②clinical research on how pathogen infections promote the occurrence and development of other diseases; ③ new diagnostic technologies for pathogen infection, immunotherapy strategies, and drug research and development.

The research center relies on the Tongji University School of Medicine and integrates the advantageous clinical disciplines of the Affiliated Tenth People's Hospital, Affiliated Pulmonary Hospital, Affiliated Dongfang Hospital, and Affiliated Dermatology Hospital. It possesses advanced detection and analysis equipment and instrument platforms. The research team is composed of many outstanding scholars, including Changjiang Scholars of the Ministry of Education, The National Science Fund for Distinguished Young Scholars, National Ten Thousand Talents Program scholars, and the National Science Fund for Excellent Young Scholars. They have undertaken 40 national-level projects, including 14 major and key projects, and have achieved a series of important original results, publishing 129 papers in international journals, including 17 papers in journals with an impact factor of over 10, such as Nature, Nature Immunology, Cell Host & Microbe, and Nature Microbiology. They have also received two Natural Science Awards from the Ministry of Education.

聯絡人：季老師

郵箱：jizhe@tongji.edu.cn

生物醫學工程與納米科學學院

Institute of Biomedical Engineering and Nanosciences

滑動查看中英文介紹

Swipe to view Chinese and English introduction

同濟大學醫學院生物醫學工程與納米科學學院成立于2008年8月，學院以培養具有國際視野、原始創新、德才兼備的創新人才為目標，以服務國家大健康戰略和臨床為導向，聚焦重大疾病的新型靶點開發、生物材料診療、醫學影像診斷及康復儀器研制，開展全方位生物醫學工程與納米科學前沿交叉研究。

學院目前擁有生物醫學工程一級碩士學位授予點及生物與醫藥工程博士學位授予點，設置“生物材料與催化醫學”、“精準醫學與系統生物學”、“生物醫學影像工程”及“智能康復與醫療設備”四個研究方向，以國家基礎科學研究中心、脊柱脊髓損傷再生修復教育部重點實驗室、干細胞與重大疾病學科創新引智基地、上海市超聲診療工程技術研究中心、上海市催化醫學前沿科學研究基地、上海市殘聯智能康復輔具與技術重點實驗室等平臺為抓手大力推動生物醫學工程學科發展。在2023年泰晤士高等教育中國學科評級中，同濟大學生物醫學工程評級為A-級。

學院現有一支28人的多學科交叉特色的專任教學科研團隊，其中包含中科院院士1名、國家杰青2名、國家優青（含海外）4名，具有副高及以上職稱20人，副高及以上專任教師中具有博士學位的比例為100%。學院現任院長為中國科學院院士、無機化學家施劍林教授。學院近年來獲批多項科技部國家重點研發計劃、科技部重點研發計劃政府間國際合作重點專項、國自然優秀青年基金、國自然面上項目、國自然青年基金、上海市基礎研究特區計劃、上海市教委科研創新計劃自然科學重大項目等。在Nature Nanotechnology, Nature Communications, JACS, Science Advances, Advanced Materials等國際高水平學術期刊發表論文200余篇，申請/授權國家發明專利60余項，實現10余項科研成果轉化，轉化金額超千萬，帶來直接/間接經濟效益數千萬元，牽頭建立行業團體標準2項。

The Institute of Biomedical Engineering and Nanosciences, School of Medicine, Tongji University was established in August 2008. The institute aims to cultivate innovative talents with international vision, innovations, moral integrity, and professional competence. We serve the national health initiative and clinical demands by focusing on the development of novel biomarkers, biomaterials-based therapeutics, medical imaging diagnosis, and rehabilitation instruments for major diseases.

Currently, the institute offers a first-class master's degree program in Biomedical Engineering and a doctoral degree program in Biology and Medicine. The research directions include "Biomaterials and Catalytic Medicine," "Precision Medicine and Systems Biology," "Biomedical Imaging Engineering," and "Intelligent Rehabilitation and Medical Equipment." The institute has excellent research platforms including the National Basic Science Research Center, the Key Laboratory of Spine and Spinal cord Injury Repair and Regeneration (Ministry of Education), the Discipline Innovation Base for Stem Cells and Major Diseases, the Shanghai Engineering Technology Research Center for Ultrasonic Diagnosis and Treatment, the Shanghai Frontier Science Research Center for Catalytic Medicine, and the Key Laboratory of Intelligent Rehabilitation Aids and Technology of the Shanghai Disabled Persons' Federation. In the 2023 Times Higher Education China Subject Ratings, Tongji University's Biomedical Engineering was rated A-.

The institute currently has 28 staff with multidisciplinary backgrounds, including 1 academician of the Chinese Academy of Sciences, 2 National Distinguished Youth Scholars, and 4 National Excellent Youth Scholars. The dean of the institute is Professor Jianlin Shi, an academician of the Chinese Academy of Sciences. In recent years, the institute has been awarded numerous national projects including key research and development plans from the Ministry of Science and Technology, key special projects of government international cooperation, the National Natural Science Foundation of China (NSFC) Excellent Youth Scholars, NSFC General Projects, NSFC Youth Fund, Shanghai Basic Research Special Zone Program, and Scientific Research Innovation Plan for Natural Science Major Projects of Shanghai Municipal. The researchers of the institute have published over 200 papers in high-level international academic journals such as Nature Nanotechnology, Nature Communications, JACS, Science Advances, and Advanced Materials. Over 60 national invention patents have been filed. More than 10 items of scientific findings were commercialized, generating direct and indirect economic benefits worth more than tens of millions of CNY. Two items of industrial standards have been initiated to be established.

聯絡人：霍老師

郵箱：mfhuo@tongji.edu.cn

公共衛生與全科學院

Public Health and General Medicine College

滑動查看中英文介紹

Swipe to view Chinese and English introduction

同濟大學醫學院公共衛生與全科學院致力于培養國家公共衛生事業的棟梁和專業精英。學院目前擁有973項目科學家、國家重點研發計劃負責人、國家基金委杰出青年和海外優青、國家級省部級專業學會主委等高層次學科領軍人才，逐步建成流行病學、臨床醫學、計算機科學、人工智能、生物遺傳學和生物信息學等多學科交叉的研究團隊。學院致力于以多學科交叉和健康醫療大數據為特色的覆蓋疾病“發生-診斷-復發-生存-管理”全過程的精準醫學研究。

目前重點研究方向主要聚焦于以下兩個：

（1）健康大數據科學：建設及管理健康大數據平臺，以大數據為基礎，循證醫學為證據，人工智能為工具，對神經精神障礙疾病、心腦血管、癌癥及其他主要慢性病開展精準的預測、預防、診斷、和治療；

（2）人群遺傳與精準醫學：重大遺傳性出生缺陷疾病的遺傳與分子機制、出生缺陷疾病動物模型與治療策略研究。

Tongji University School of Medicine's Public Health and General Medicine College is dedicated to cultivating the pillars and professional elites of the national public health sector. The college currently boasts high-level disciplinary leaders, including scientists from the 973 Program, heads of national key research and development projects, outstanding young scholars recognized by the National Natural Science Foundation, and chairs of national and provincial professional societies. It is gradually establishing interdisciplinary research teams in epidemiology, clinical medicine, computer science, artificial intelligence, genetics, and bioinformatics. The college focuses on precision medicine research that covers the entire process of disease "occurrence-diagnosis-recurrence-survival-management" characterized by interdisciplinary collaboration and health care big data.

Our current key research directions mainly focus on the following two areas:

(1) Health Big Data Science: Building and managing a health big data platform that utilizes big data as the foundation, evidence-based medicine as the proof, and artificial intelligence as the tool to conduct precise predictions, prevention, diagnosis, and treatment of neuropsychiatric disorders, cardiovascular diseases, cancers, and other major chronic diseases.

(2) Population Genetics and Precision Medicine: Researching the genetic and molecular mechanisms of significant hereditary birth defect diseases, as well as developing animal models and treatment strategies for these birth defects.

聯絡人：史老師

郵箱：xiujuansh@tongji.edu.cn

藥學院

School of Pharmaceutical Sciences

滑動查看中英文介紹

Swipe to view Chinese and English introduction

同濟大學醫學院藥學院始于1907年建校之初的醫學根基，2011年成為藥學一級學科碩士學位授權點。藥學院聚焦藥理學、藥物化學、藥劑學、微生物與生物技術藥物學、藥物分析學五大方向，在抗耐藥真菌藥物、心血管及眼科藥理學、靶向遞送系統、海洋藥物等領域形成特色優勢。藥理學與毒理學自2017年起穩居ESI全球前1%。

藥學院擁有國家級領軍人才（杰青、優青、海外優青）及省部級帶頭人組成的師資團隊，依托教育部心律失常重點實驗室、病原體與宿主互作重點實驗室、上海市結核病重點實驗室等高水平平臺。近五年主持國家重點研發計劃、國家自然科學基金等50余項，發表SCI論文120余篇，科研資源充沛。

藥學院實施"卓越人才培養計劃"，以數智化、綠色化、融合化為引領，培養具備國際視野、創新能力與社會責任感，能勝任藥物研發、生產、監管及教育的高層次藥學人才。

The School of Pharmaceutical Sciences at Tongji University School of Medicine originated from the medical foundation established in 1907 and was officially authorized to offer a master’s degree in the primary discipline of pharmacy in 2011. The School specializes in five key areas: pharmacology, medicinal chemistry, pharmaceutics, microbiology and biotechnology pharmaceuticals, and pharmaceutical analysis. It has developed notable expertise in areas such as antifungal drugs targeting resistant strains, cardiovascular and ophthalmic pharmacology, targeted drug delivery systems, and marine-derived pharmaceuticals. Since 2017, its pharmacology and toxicology programs have consistently ranked within the top 1% worldwide according to ESI.

The faculty includes nationally recognized experts, such as Distinguished Young Scholars, Excellent Young Scholars, and Outstanding Overseas Young Scholars, along with leaders at provincial and ministerial levels. The School benefits from prestigious platforms like the Ministry of Education Key Laboratory of Cardiac Arrhythmia, the Key Laboratory of Pathogen-Host Interaction, and the Shanghai Key Laboratory of Tuberculosis. In the past five years, it has led over 50 projects, including those funded by the National Key R&D Program and the National Natural Science Foundation, and has published more than 120 papers indexed by SCI, supported by substantial research resources.

The Institute of Pharmaceutical Sciences runs the "Excellence Talent Training Program," which emphasizes digital intelligence, sustainability, and integration. This program aims to develop high-caliber pharmacy professionals with a global perspective, innovative skills, and a strong sense of social responsibility, preparing them to excel in drug research and development, manufacturing, regulation, and education.

聯絡人：張老師

郵箱：zhangjieping@tongji.edu.cn

康復醫學院

School of Rehabilitation Sciences

滑動查看中英文介紹

Swipe to view Chinese and English introduction

同濟大學醫學院康復醫學院前身為 2013 年成立的康復治療學系，2024 年升格為康復醫學院（籌）。學院依托同濟大學醫學院及附屬醫院建設，是服務“健康中國”戰略、推動康復醫學與多學科交叉融合的創新型學院，現任院長為同濟大學附屬養志康復醫院院長靳令經教授。

學院聚焦智能康復、再生康復、康復工程等前沿方向，充分融合同濟大學多學科優勢，構建起覆蓋康復醫學、康復治療科學、智能康復工程、聽力語言與認知行為科學、再生康復醫學五個方向的學科體系，形成“醫工結合、科教融合、臨床轉化”一體化的高層次人才培養與科研創新高地。其科研平臺實力雄厚，擁有康復醫學國家臨床重點專科、中國康復醫學會康復醫學研究中心、上海市康復醫學重中之重研究中心、同濟大學智能康復研究院等學科平臺。

學院師資力量強大且成果豐碩，現有交叉學科團隊專任教師 65 人，其中正高級職稱 42 人，博士生導師 48 人，包含國家“萬人計劃”、長江學者、國家杰青等國家級人才 17 人。近五年，學院承擔國家重點研發計劃、國自然重點項目等國家級項目 70 余項，發表高水平 SCI 論文 580 余篇，獲授權專利近 30 項，多項成果實現臨床轉化。在人才培養上，學院推行“基礎理論 + 臨床實踐 + 工程技術”三導師制培養模式，康復物理治療專業成績亮眼，在軟科、武書連等排行榜中連續多年獲評全國 A + 等級，2019 年與 2025 年兩次通過世界物理治療聯盟（WPT）國際認證，2022 年入選教育部國家級一流本科專業建設點，畢業生就業率持續超過 99%。

此外，學院積極開展國際合作，與芝加哥康復醫院、多倫多大學、帝國理工學院等國際一流機構共建聯合實驗室，致力于建設具有全球影響力的康復科學與技術創新中心，不斷提升自身在國際康復領域的知名度與影響力。

The School of Rehabilitation Medicine at Tongji University School of Medicine originated from the Department of Rehabilitation Therapy, established in 2013, and was upgraded to the School of Rehabilitation Medicine (Provisional) in 2024. Built upon the foundation of Tongji University School of Medicine and its affiliated hospitals, the School is an innovative institution dedicated to serving the national "Healthy China" strategy and promoting the integration of rehabilitation medicine with multiple disciplines. The current Dean is Professor Jin Lingjing, President of Yangzhi Rehabilitation Hospital Affiliated with Tongji University.

Focusing on cutting-edge fields such as intelligent rehabilitation, regenerative rehabilitation, and rehabilitation engineering, the School fully leverages Tongji University's multidisciplinary strengths to construct an academic system covering five major directions: Rehabilitation Medicine, Rehabilitation Therapy Science, Intelligent Rehabilitation Engineering, Hearing-Speech-Language and Cognitive Behavioral Science, and Regenerative Rehabilitation Medicine. It has established an integrated platform for high-level talent cultivation and scientific research innovation characterized by the "integration of medicine and engineering, fusion of science and education, and clinical translation."

The School boasts robust research platforms, including the National Clinical Key Specialty in Rehabilitation Medicine, the Chinese Rehabilitation Medicine Association Rehabilitation Medicine Research Center, the Shanghai Key Priority Research Center for Rehabilitation Medicine, and the Tongji University Intelligent Rehabilitation Research Institute.

The School possesses a strong faculty with outstanding achievements. It currently has 65 full-time interdisciplinary faculty members, including 42 full professors and 48 doctoral supervisors. Among them are 17 national-level talents, such as recipients of the National "Ten Thousand Talents Program," Cheung Kong Scholars, and National Science Fund for Distinguished Young Scholars. Over the past five years, the School has undertaken more than 70 national-level projects, including National Key R&D Program projects and National Natural Science Foundation of China key projects. It has published over 580 high-impact SCI papers, obtained nearly 30 authorized patents, and successfully translated multiple research findings into clinical applications. In talent cultivation, the School implements a "Three-Mentor System" integrating "basic theory + clinical practice + engineering technology." Its Rehabilitation Physical Therapy program has achieved remarkable results, consistently receiving an A+ grade in national rankings such as those by ShanghaiRanking and Wu Shulian. The program passed the international certification by the World Physiotherapy (WPT) in both 2019 and 2025, and was selected for the National First-Class Undergraduate Major Construction Point by the Ministry of Education in 2022. The employment rate for its graduates has consistently exceeded 99%.

Furthermore, the School actively engages in international collaboration, having established joint laboratories with world-renowned institutions such as the Shirley Ryan AbilityLab (formerly the Rehabilitation Institute of Chicago), the University of Toronto, and Imperial College London. It is committed to building a globally influential center for rehabilitation science and technological innovation, continuously enhancing its reputation and impact in the international rehabilitation field.

聯絡人：沈老師

郵箱：zshxia18003@tongji.edu.cn

學院將組織專家對報名信息進行評估，邀請符合學院戰略發展需求的學者參會，同時根據受邀者情況推薦申請大學以下職位：

1

青年百人計劃

(1) 青年百人計劃A崗

?基本條件：

在所從事研究的學科領域中取得高水平科研成果，有突出的學術創新能力和發展潛力，學術成果達到國家級高層次青年人才同等水平。具有博士學位，年齡一般不超過40周歲。聘期內全職在崗工作且與同濟大學簽訂聘用合同。

?支持政策：

1.聘任為長聘教職；

2.提供具有競爭力的薪酬；

3.為引進的青百受聘學者提供啟動經費和一次性補助；

4.所在學院提供必需的辦公和科研用房，在團隊建設、研究生招生、重大科研項目申請等方面給予充分支持；

5.提供良好的醫療保健服務。

(2) 青年百人計劃B崗

?基本條件：

在所從事研究的學科領域取得高水平科研成果，有較強的學術創新能力和沖擊國家級高層次青年人才計劃的水平，具備團隊合作精神。具有博士學位，年齡一般不超過35周歲。聘期內全職到崗工作且與同濟大學簽訂聘用合同。

?支持政策：

1.聘任為特聘研究員；

2.提供具有競爭力的薪酬；

3.為引進的青百受聘學者提供啟動經費和住房補助；

4.所在學院提供必需的辦公和科研用房，在團隊建設、研究生招生、重大科研項目申請等方面給予充分支持；

5.提供良好的醫療保健服務。

2

長聘教職體系

(1) 長聘教授

?基本條件：

申請人應活躍在教學科研第一線，取得國際同行認可的突出學術成就，具有很高的國際知名度和影響力，在教學和研究生培養方面表現優秀并取得重要成果，在所在院系的學科建設中起到重要作用，達到世界一流大學（學科）終身教授的水平。應具有博士學位，年齡原則上不超過45周歲。

?支持政策：

1.提供具有競爭力的薪酬。

2.所在學院提供必需的辦公和科研用房，并在團隊建設、研究生招生、重大科研項目申請等方面給予優先支持；

3.提供良好的醫療保健服務。

(2) 預聘副教授

?基本條件：

申請人具備良好的教學能力，在研究方面已取得具有原創性和重要性的研究成果和良好發展潛力，在領域內有一定的知名度和影響力。應具有博士學位，年齡原則上不超過40周歲。

?支持政策：

1.提供具有競爭力的薪酬。

2.所在學院提供必需的辦公和科研用房，并在團隊建設、研究生招生、重大科研項目申請等方面給予支持；

3.提供良好的醫療保健服務。

(3) 預聘助理教授

?基本條件：

申請人具有良好的學術能力，較強的創新活力和學術發展潛力。應具有博士學位，原則上要有博士后經歷或相應的科研工作經歷，年齡一般不超過35周歲。

?支持政策：

1.提供具有競爭力的薪酬。

2.所在學院提供必需的辦公和科研用房，并在研究生招生、重大科研項目申請等方面給予支持；

3.提供良好的醫療保健服務。

青年論壇聯系人：

孟老師

電話：021-51030895

郵箱：1753420@tongji.edu.cn

長聘教職聯系人：

徐老師

電話：021-51030895

郵箱：xsh91351@tongji.edu.cn

來源：醫學院人事人才辦公室

同濟Med-Go全球開源！

2025-11-18

同濟大學醫學生命“十五五”規劃專題會議舉行

2025-10-20

同醫

精誠濟世

明道致遠

微信號｜tongji_med

更多內容敬請關注